It found that TGX-221 was a common sensitive drug of AKR1B10 and SPP1, which may play a role in inhibiting or delaying the progression of NAFLD and improve the prognosis of NAFLD-HCC (Figure 8M). This evidence concerns the gene SPP1 and metabolic dysfunction-associated steatotic liver disease.